RIDAURA Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Ridaura, and what generic alternatives are available?
Ridaura is a drug marketed by Sebela Ireland Ltd and is included in one NDA.
The generic ingredient in RIDAURA is auranofin. There are seven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the auranofin profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for RIDAURA?
- What are the global sales for RIDAURA?
- What is Average Wholesale Price for RIDAURA?
Summary for RIDAURA
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 8 |
| Clinical Trials: | 7 |
| Patent Applications: | 2 |
| Drug Prices: | Drug price information for RIDAURA |
| What excipients (inactive ingredients) are in RIDAURA? | RIDAURA excipients list |
| DailyMed Link: | RIDAURA at DailyMed |
Recent Clinical Trials for RIDAURA
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Mayo Clinic | Phase 2 |
| National Cancer Institute (NCI) | Phase 2 |
| Mayo Clinic | Phase 1 |
US Patents and Regulatory Information for RIDAURA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sebela Ireland Ltd | RIDAURA | auranofin | CAPSULE;ORAL | 018689-001 | May 24, 1985 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for RIDAURA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Sebela Ireland Ltd | RIDAURA | auranofin | CAPSULE;ORAL | 018689-001 | May 24, 1985 | ⤷ Sign Up | ⤷ Sign Up |
| Sebela Ireland Ltd | RIDAURA | auranofin | CAPSULE;ORAL | 018689-001 | May 24, 1985 | ⤷ Sign Up | ⤷ Sign Up |
| Sebela Ireland Ltd | RIDAURA | auranofin | CAPSULE;ORAL | 018689-001 | May 24, 1985 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for RIDAURA
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
